Study identifier:D134BR00005
ClinicalTrials.gov identifier:NCT07221331
EudraCT identifier:N/A
CTIS identifier:N/A
Prevalence, Clinical Characteristics, Progression, and Management of Neurofibromatosis Type 1 in Egypt (NF1-Egy)
Neurofibromatosis Type 1
N/A
No
-
All
200
Observational
n/a - n/a
Allocation: N/A
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
Verified 01 Jan 2026 by AstraZeneca
AstraZeneca
-
No locations available
| Arms | Assigned Interventions |
|---|